NAD+ Research Guide — Peptide Mag

Overview

What is NAD+?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell of every living organism, essential for hundreds of metabolic reactions. It exists in oxidized (NAD+) and reduced (NADH) forms and serves as a critical electron carrier in mitochondrial energy production. Beyond its role in metabolism, NAD+ is a required substrate for sirtuins (SIRT1-7), a family of enzymes involved in DNA repair, gene silencing, chromosomal stability, and cellular stress responses. It is also consumed by PARP enzymes during DNA damage repair and by CD38, a NADase whose activity increases with aging.

NAD+ levels decline significantly with age, falling by approximately 50% between ages 40 and 60 in multiple tissue types. This decline is now recognized as a hallmark of aging and a contributing factor to mitochondrial dysfunction, impaired DNA repair, inflammatory activation (inflammaging), and metabolic disease. The discovery that NAD+ supplementation could reverse markers of aging in mouse models by Dr. David Sinclair at Harvard Medical School catalyzed an explosion of research into NAD+ restoration as a therapeutic strategy.

Injectable NAD+ provides direct delivery of the molecule, bypassing the complex and inefficient oral conversion pathways required by precursors like NMN and NR. While oral precursors must be absorbed, converted through multiple enzymatic steps, and survive first-pass metabolism, injectable NAD+ delivers the active form directly to circulation. IV NAD+ infusions have been used clinically for neurodegenerative conditions, addiction recovery, and chronic fatigue, while subcutaneous injections offer a more practical approach for regular administration.

Science

Mechanism of Action

NAD+ is not a signaling molecule in the traditional sense — it is a metabolic substrate consumed by multiple enzyme families. Its therapeutic value lies in restoring intracellular levels to support these critical enzymatic processes.

Sirtuin Activation (SIRT1-7)

Sirtuins are NAD+-dependent deacetylases that regulate gene expression, DNA repair, and metabolic pathways. SIRT1 and SIRT3 are particularly important: SIRT1 deacetylates PGC-1alpha (promoting mitochondrial biogenesis) and p53 (modulating cell cycle control), while SIRT3 directly regulates mitochondrial enzyme activity. When NAD+ levels decline, sirtuin activity decreases proportionally, impairing these protective functions [1].

PARP-Mediated DNA Repair

Poly(ADP-ribose) polymerases (PARPs) consume NAD+ to synthesize poly(ADP-ribose) chains at DNA damage sites, recruiting repair enzymes. PARP1 is the largest consumer of NAD+ in the cell during genotoxic stress. With age, accumulated DNA damage increases PARP activity, further depleting NAD+ and creating a vicious cycle of declining NAD+ and impaired repair capacity [2].

Mitochondrial Electron Transport

The NAD+/NADH ratio is fundamental to mitochondrial oxidative phosphorylation. NAD+ accepts electrons from metabolic substrates (glycolysis, TCA cycle), becoming NADH, which donates electrons to Complex I of the electron transport chain. Declining NAD+ levels shift the NAD+/NADH ratio, reducing the driving force for ATP production and contributing to the energy deficit characteristic of aging tissues [3].

CD38 and Age-Related NAD+ Decline

CD38 is a NADase (enzyme that degrades NAD+) whose expression increases with age, particularly in immune cells and inflammatory tissue. Rising CD38 activity is now considered a primary driver of age-related NAD+ decline — not reduced synthesis, but increased degradation. This discovery has shifted therapeutic strategies toward both NAD+ replenishment and CD38 inhibition [4].

Dosing

Dosing Protocol

NAD+ dosing varies significantly by administration route. Subcutaneous injection is the most practical for regular use, while IV infusion provides higher bioavailability but requires more time and clinical infrastructure.

Route	Dose	Frequency	Duration	Notes
Subcutaneous	50–200 mg	Daily or every other day	Ongoing	Abdominal SubQ; may cause injection site discomfort
Intravenous	250–750 mg	Weekly or bi-weekly	Ongoing	Slow IV drip over 2–4 hours; clinical setting
Loading protocol	500 mg IV	Daily for 3–5 days	Loading phase	Initial loading, then transition to maintenance
Maintenance SubQ	100 mg	Every other day	Ongoing	Common maintenance after IV loading

Dosing Notes
SubQ injections of NAD+ commonly cause a stinging or burning sensation at the injection site. This is normal and resolves within minutes.
Splitting larger SubQ doses across multiple injection sites can reduce discomfort.
Administer earlier in the day — NAD+ is energizing and can cause insomnia if injected in the evening.
IV infusions must be administered slowly. Rapid infusion causes nausea, chest tightness, and flushing.

Preparation

Reconstitution Guide

Reconstitute lyophilized NAD+ with bacteriostatic water. NAD+ dissolves readily but the resulting solution is sensitive to light. Never shake the vial.

Remove the plastic cap from the vial and wipe the rubber stopper with an alcohol swab. Allow to dry completely.
Draw the appropriate volume of bacteriostatic water into a sterile syringe. For a 500 mg vial, use 5 mL for 100 mg/mL. For a 1000 mg vial, use 10 mL for 100 mg/mL.
Insert the needle through the rubber stopper at a slight angle. Inject the water slowly against the inner wall of the vial — do not spray directly onto the powder.
Allow the vial to sit for 1–2 minutes. Gently roll the vial between your palms if needed. Do not shake or vortex.
The solution should be clear to slightly amber. Discard if you observe any cloudiness, particulate matter, or strong discoloration.

500 mg vial + 5 mL BAC water: Concentration = 100 mg/mL

100 mg dose = 100 units (1 mL) on a 100-unit insulin syringe

200 mg dose = 2 mL (use a standard syringe)

1000 mg vial + 10 mL BAC water: Concentration = 100 mg/mL

Doses per 500 mg vial at 100 mg: 5 doses

Supplies Needed (30-Day Maintenance at 100 mg EOD)
2 vials NAD+ (500 mg each) — provides 10 doses, covers ~20 days; or 1 vial NAD+ (1000 mg) for 10 doses
2 vials bacteriostatic water (30 mL each)
15 insulin syringes (29–31 gauge, 100-unit)
Alcohol prep pads

Administration

Injection Technique

NAD+ can be administered subcutaneously or intravenously. SubQ is the standard self-administration route. IV infusion should be performed in a clinical setting.

Clean the injection site with an alcohol swab and allow it to air dry completely (approximately 30 seconds). Common SubQ sites: lower abdomen (2 inches from navel) or upper thigh.
Draw the dose. Insert the needle into the vial through the rubber stopper. Invert the vial and draw the calculated volume slowly. Tap the syringe to move any air bubbles to the top, then push them out gently.
Pinch the skin at the injection site to create a fold of subcutaneous tissue. Insert the needle at a 45-degree angle in a quick, smooth motion. Release the skin fold.
Inject slowly. Depress the plunger steadily over 10–15 seconds. NAD+ can sting — slower injection reduces discomfort. Withdraw the needle and apply gentle pressure with a clean swab.

Managing Injection Discomfort

NAD+ SubQ injections are known to cause a stinging or burning sensation that lasts 1–5 minutes. Strategies to reduce discomfort: inject slowly (15+ seconds), split large doses across 2 sites, allow the solution to reach room temperature before injecting, and use ice on the site for 30 seconds before injection to numb the area. The sensation is harmless and diminishes with repeated use.

Storage

Storage & Stability

NAD+ is more sensitive to degradation than most peptides, particularly to light and heat. Proper storage is critical.

Lyophilized (Powder)

2–8°C (36–46°F)

Refrigerator, protected from light. Stable 12+ months.

Lyophilized (Long-term)

-20°C (-4°F)

Freezer. Extended stability beyond 18 months.

Reconstituted

2–8°C (36–46°F)

Refrigerate immediately, protect from light. Use within 14 days.

Avoid

Light exposure; do not freeze solution

NAD+ is light-sensitive. Wrap vial in foil if possible.

Storage Tips
NAD+ degrades faster in solution than most peptides. The 14-day reconstituted window is shorter than typical peptides (30 days).
Wrap reconstituted vials in aluminum foil to protect from light.
Never re-freeze a reconstituted vial. Discard if left at room temperature for more than 2 hours.
Label reconstituted vials with the date to track the 14-day use window.

Safety

Side Effects & Considerations

NAD+ is a naturally occurring molecule in the body, and injectable supplementation is generally well-tolerated. Most side effects are route-dependent and transient.

SubQ Administration

Injection site pain, stinging, and redness — the most common complaint. NAD+ solution is inherently irritating to tissue. Resolves within minutes.
Mild flushing and warmth — typically brief.
Insomnia if administered too late in the day — NAD+ is energizing and can disrupt sleep. Administer before 2 PM.

IV Administration

Nausea during infusion — dose-rate dependent. Slow the drip rate to reduce.
Chest tightness or pressure sensation — reported during rapid IV infusion. Resolves when rate is decreased.
Headache and lightheadedness — typically during or shortly after IV infusion.
Abdominal cramping — occasional, more common at higher IV doses.

Important

NAD+ is a naturally occurring coenzyme, not a pharmaceutical drug. Injectable NAD+ has not been FDA-approved for any specific indication. Clinical use has been documented in integrative medicine settings for addiction recovery, chronic fatigue, and neurodegenerative conditions. All information presented here reflects published research and clinical observations.

Protocols

Stacking Protocols

NAD+ is frequently used alongside other longevity-focused compounds. Its role as a metabolic substrate makes it complementary to many interventions rather than redundant.

NAD+ + Epithalon (Longevity Stack)

NAD+ supports cellular energy and sirtuin activation while Epithalon (epitalon) activates telomerase, potentially maintaining telomere length. The combination targets two distinct hallmarks of aging: metabolic decline and genomic instability.

Compound	Dose	Frequency	Duration
NAD+	100 mg SubQ	Every other day	Ongoing
Epithalon	5 mg SubQ	Daily for 10–20 days	1–2 cycles per year

Lifestyle Factors

NAD+ levels are influenced by several modifiable lifestyle factors:

Exercise: Both aerobic and resistance exercise upregulate NAMPT (the rate-limiting enzyme in NAD+ salvage synthesis), independently boosting NAD+ levels.
Caloric restriction / Time-restricted eating: Fasting states increase NAD+ through AMPK-mediated NAMPT activation.
Sleep: NAD+ levels follow circadian rhythms. Disrupted sleep patterns impair NAD+ cycling.
Avoid excess alcohol: Alcohol metabolism consumes NAD+ (alcohol dehydrogenase and aldehyde dehydrogenase both require NAD+), acutely depleting cellular stores.

Researchers studying NAD+ often investigate these related compounds:

References

Literature & Citations

Yoshino J, Baur JA, Imai SI. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018;27(3):513-528. PubMed
Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018;27(3):529-547. PubMed
Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213. PubMed
Braidy N, Berg J, Clement J, et al. Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases. Antioxid Redox Signal. 2019;30(2):187-214. PubMed
Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23(6):1127-1139. PubMed
Imai SI, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471. PubMed
Katsyuba E, Romani M, Hofer D, Auwerx J. NAD+ homeostasis in health and disease. Nat Metab. 2020;2(1):9-31. PubMed

NAD+